Log in
NASDAQ:PAND

Pandion Therapeutics Earnings Date, Estimates & History

$17.32
-0.29 (-1.65 %)
(As of 12/1/2020 12:00 AM ET)
Add
Compare
Today's Range
$17.24
Now: $17.32
$17.82
50-Day Range
$10.73
MA: $13.47
$18.09
52-Week Range
$10.28
Now: $17.32
$27.75
Volume21,536 shs
Average Volume131,609 shs
Market Capitalization$511.29 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Earnings

Pandion Therapeutics (NASDAQ:PAND) Earnings Information

Pandion Therapeutics last posted its quarterly earnings results on November 16th, 2020. The reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.07. Pandion Therapeutics has generated $0.00 earnings per share over the last year. Pandion Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 15th, 2021 based off prior year's report dates.

Pandion Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Pandion Therapeutics (NASDAQ:PAND) Earnings Estimates

2020 EPS Consensus Estimate: ($1.70)
2021 EPS Consensus Estimate: ($1.65)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20201($0.93)($0.93)($0.93)
Q3 20201($0.42)($0.42)($0.42)
Q4 20201($0.35)($0.35)($0.35)
Q1 20211($0.37)($0.37)($0.37)
Q2 20211($0.42)($0.42)($0.42)
Q3 20211($0.44)($0.44)($0.44)
Q4 20211($0.42)($0.42)($0.42)

Pandion Therapeutics (NASDAQ PAND) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
2/15/2021
(Estimated)
       
11/16/20209/30/2020($0.44)($0.51)($0.51)N/A
8/31/20206/30/2020($0.61)($10.15)($10.15)$1.00 million$1.96 millionN/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.